Anti-Tumor Drugs Market Report 2026

The anti-tumor drugs market size has grown rapidly in recent years. It will grow from $206.81 billion in 2025 to $229.63 billion in 2026 at a compound annual growth rate (CAGR) of 11%. The growth in the historic period can be attributed to limited availability of targeted therapy drugs, reliance on conventional cytotoxic drugs, growing incidence of major cancers, development of basic hospital pharmacy infrastructure, increasing awareness of cancer treatment options.

The anti-tumor drugs market size is expected to see rapid growth in the next few years. It will grow to $345.02 billion in 2030 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to advancements in gene therapy and immunotherapy, expansion of precision medicine initiatives, rising pharmaceutical R&D investments, growing online pharmacy adoption, development of novel drug delivery systems. Major trends in the forecast period include rising adoption of personalized cancer therapies, increasing investment in immunotherapy and targeted treatments, expansion of injectable and oral anti-tumor drug formulations, growth in hospital and oncology clinic pharmacies, focus on drug safety, compliance, and pharmacovigilance.

The rising incidence of cancer is anticipated to drive the growth of the anti-tumor drugs market in the coming years. Cancer encompasses a group of diseases marked by the uncontrolled growth and spread of abnormal cells within the body, which can invade surrounding tissues and spread to distant organs through the blood and lymphatic systems. The growing occurrence of cancer is largely attributed to unhealthy lifestyle factors such as poor dietary habits, physical inactivity, smoking, excessive alcohol intake, and prolonged exposure to environmental pollutants, all of which significantly increase the risk of developing various cancers. Anti-tumor drugs help fight cancer by targeting and eliminating malignant cells, suppressing tumor growth, and slowing or preventing disease progression. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government healthcare agency, there were 354,820 newly diagnosed cancer cases in 2023, averaging 972 cases per day, which was 8,605 more than in 2022. Therefore, the increasing incidence of cancer is contributing to the growth of the anti-tumor drugs market.

Major companies operating in the anti-tumor drugs market are concentrating on the development of innovative therapies, such as targeted treatments for breast cancer, to improve clinical outcomes in hormone receptor-positive metastatic cases. Targeted breast cancer therapies use precision-based approaches that specifically interfere with cancer cell growth pathways, thereby reducing harm to healthy cells and enhancing treatment tolerability. For instance, in January 2023, Sun Pharmaceutical Industries Ltd., an India-based pharmaceutical company, introduced Palbociclib, a novel anti-cancer drug, for the treatment of advanced breast cancer in India. Palbociclib is a highly selective oral inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are critical regulators of cell cycle progression. By inhibiting the transition from the G1 phase to the S phase of the cell cycle, the drug induces cell cycle arrest and restricts tumor growth. It is primarily indicated for hormone receptor-positive, HER2-negative advanced breast cancer, addressing uncontrolled cancer cell proliferation.

In February 2024, AbbVie Inc., a US-based biopharmaceutical company, acquired ImmunoGen for $10.1 billion. This acquisition is intended to enhance AbbVie’s oncology portfolio, broaden its pipeline of innovative cancer treatments, and strengthen its competitive position in the global biopharmaceutical market. ImmunoGen, Inc. is a US-based biotechnology company specializing in anti-tumor drug development.

Major companies operating in the anti-tumor drugs market are Pfizer Inc, Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG., GlaxoSmithKline plc, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim GmbH, Astellas Pharma Inc., Incyte Corporation, BeOne Medicines Inc., Getwell Oncology Pvt Ltd., Shanghai Haihe Pharmaceutical Co. Ltd.

North America was the largest region in the anti-tumor drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anti-tumor drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the anti-tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the anti-tumor drugs market by increasing costs of imported active pharmaceutical ingredients (APIs) and advanced formulations, impacting production and pricing. Injectable and targeted therapy drugs are particularly affected, with regions such as Asia-Pacific, including China and India, facing significant import duties. This has led to supply chain disruptions and higher drug costs. On the positive side, tariffs have encouraged domestic manufacturing, local R&D investment, and innovation in cost-efficient production methods.

The anti-tumor drugs market research report is one of a series of new reports that provides anti-tumor drugs market statistics, including anti-tumor drugs industry global market size, regional shares, competitors with a anti-tumor drugs market share, detailed anti-tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-tumor drugs industry. This anti-tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Anti-tumor drugs are pharmaceutical agents developed to prevent, control, or treat the growth and spread of tumors, especially malignant cancers. These drugs act by destroying cancer cells, inhibiting cell division, blocking signaling pathways that drive tumor growth, or activating the immune system to recognize and attack cancer cells. Anti-tumor therapies are often used alone or in combination with surgery, radiation, or other treatment modalities to improve clinical outcomes and reduce the likelihood of cancer recurrence.

The main drug types of anti-tumor drugs include cytotoxic drugs, targeted therapy drugs, hormonal therapy drugs, immunotherapy drugs, and others. Cytotoxic drugs are medications that damage or kill cells and are primarily used to eliminate cancer cells by disrupting their growth and division. These drugs are applied in the treatment of various cancers, including lung cancer, breast cancer, colorectal cancer, prostate cancer, and other types. They are administered through multiple routes, such as oral and injectable forms, among others, and are distributed through channels including hospital pharmacies, retail pharmacies, online pharmacies, and others.

The anti-tumor drugs market consists of sales of opdevlimidivo, avastin, herceptin, and revlimid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.